Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trial.
/in Dendritic Cells, Esophageal Carcinoma, International PublicationsDendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
/in Dendritic Cells, International Publications, Prostate CancerShort-course preoperative radiotherapy combined with chemotherapy, delayed surgery and local hyperthermia for rectal cancer: a phase II study
/in Colorectal Cancer, Hyperthermia, International PublicationsTargeting therapy-resistant cancer stem cells by hyperthermia
/in Hyperthermia, International PublicationsA Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
/in Dendritic Cells, Esophageal Carcinoma, International PublicationsHistory and current state of immunotherapy in glioma and brain metastasis
/in Glioblastoma, International PublicationsImmunotherapy for the treatment of multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaChemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis
/in Esophageal Carcinoma, Hyperthermia, International PublicationsTargeting immune checkpoints in malignant glioma
/in Checkpoint-Inhibitors, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer